Bringing Cancer Screenings to the Community Can Increase Today's Diagnosis Number and Get Patients to Care Sooner
In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.
Related: What the 'Pathway Approach' Can Do to Improve Health Outcomes, Reduce Testing Delays For Cancer Care
In this final video of a three-part video series, Editor of Managed Healthcare Executive, Briana Contreras, speaks with Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, about why shortening the gap of time it takes to receive a cancer diagnosis and getting the treatment for it is critical to ensuring better patient outcomes. In the discussion Dr. Fesko shares a key takeaway from Quest's recent Health Trends Survey, which is how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. He adds bringing cancer screenings to the community can increase diagnosis numbers which can lead to care sooner.
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Survey Reveals Cancer Doctors Struggle to Keep Up as Treatments Advance Quickly
May 11th 2025A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.
Read More
The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.
Read More
